secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001764013-23-000131
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports Q2 FY2024 net loss of $58.7M; Phase 1 data supports IMVT-1402 best-in-class potential
--------------------------------------------------------------------------------

- Net loss of $58.7M ($0.45/share) for Sep Q, vs. $47.9M ($0.41) a year ago; wider loss on higher R&D.
- Initial Phase 1 data for IMVT-1402 showed dose-dependent IgG reductions without significant albumin or LDL changes.
- Raised ~$467M net in October 2023 public/private offering; pro forma cash $737M as of Sep 30.
- Expects initial 600mg MAD cohort data for IMVT-1402 in Nov 2023; Phase 2 Graves' data by year-end 2023.
- Phase 3 MG top-line data expected H2 2024; TED data H1 2025; CIDP Phase 2b data H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000131/0001764013-23-000131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000131/imvt-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001764013-23-000131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer